Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I Trial, With an Expansion Cohort: Macrophage Conditioning to Synergize With CAR-T in High-risk Lymphoma (MAC-SHIFT)

NCT07638982 is registered in ClinicalTrials.gov with Northside Hospital, Inc. as lead sponsor.

NCT NCT07638982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07638982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I Trial, With an Expansion Cohort: Macrophage Conditioning to Synergize With CAR-T in High-risk Lymphoma (MAC-SHIFT)
Lead sponsor
Northside Hospital, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2029
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma (dlbcl), follicular grade 3 lymphoma, high-grade b-cell lymphoma (hgbcl), high-grade b-cell lymphoma, nos, pmbcl, transformed indolent b-cell non-hodgkin lymphoma to diffuse large b-cell lymphoma